AI in Cancer Diagnostics
AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the ai in cancer diagnostics market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[182 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.

AI in Cancer Diagnostics Market
To learn more about this report, request a free PDF copy

Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.

Regional Insights

In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.

Market Dynamics

The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Prevalence of cancer among the global population
    • Proliferating adoption in several cancer screening programs worldwide
    • Exponential shift towards non-invasive cancer diagnosis
  • Market Restraints
    • High cost and shortage of trained oncologists
  • Market Opportunities
    • Technological improvements in cancer diagnostics
    • Government investments in using AI in cancer diagnostics and treatments
  • Market Challenges
    • Vulnerability to cyberattacks and data breaches
Market Segmentation Analysis
  • Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error

    Hardware components are the physical tools and devices utilized in the diagnostic process including AI-enabled imaging devices, high-throughput screening platforms, and biopsy analyzers. These tools often integrate AI algorithms directly into their operation, facilitating real-time analysis and diagnostics. Services in AI cancer diagnostics include consultation, installation, maintenance, and training provided by AI companies to healthcare institutions. These services ensure that the AI systems are effectively integrated into the existing clinical workflows and that healthcare professionals are properly trained to use these technologies. Software constitutes the AI algorithms, applications, and platforms used to analyze medical data and assist in diagnostic decisions. This includes machine learning models that interpret imaging, genomic data, and electronic health records (EHRs) to identify patterns typical of cancerous processes.

  • Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification

    AI-driven diagnostic methods for brain tumors are becoming essential due to the complexity of neural structures and the critical need for precise tumor classification and boundary delineation. Advanced algorithms can assist in the early identification of gliomas, meningiomas, and other brain tumors from imaging data with higher accuracy than traditional methods. Breast cancer diagnostics strongly benefit from AI for tasks such as mammography interpretation, ultrasound analysis, and histopathology. The need for more precise diagnostic tools becomes evident, considering the high prevalence of breast cancer and the importance of early detection for successful treatment. Colorectal cancer screening often relies on colonoscopy procedures, where AI is applied to enhance polyp detection rates. AI-enabled platforms analyze tissue scans and endoscopic images, offering a higher predictive accuracy for polyp malignancy. In lung cancer diagnostics, AI applications focus on chest CT scans and X-ray interpretation to detect small, early-stage tumors. AI systems in this segment prioritize the mitigation of false positives and the enhancement of detection rates for small nodules. AI is transforming the field of prostate cancer diagnostics through the analysis of MRI images and histopathological slides. The AI platforms are significant in providing tailored treatment options and aiding in precision medicine. Dermatological applications of AI focus on the analysis of skin lesion images to identify potential malignancies such as melanoma. This is particularly need-driven due to the sheer volume of skin lesions and the need for early and scalable screening methods.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the AI in Cancer Diagnostics Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the AI in Cancer Diagnostics Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the AI in Cancer Diagnostics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the AI in Cancer Diagnostics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the AI in Cancer Diagnostics Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the AI in Cancer Diagnostics Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the AI in Cancer Diagnostics Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the AI in Cancer Diagnostics Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the AI in Cancer Diagnostics Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the AI in Cancer Diagnostics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer

    Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]

  • ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions

    ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]

  • Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses

    F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

AI in Cancer Diagnostics Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Hardware
    • Services
    • Software
  • Deployment
    • Cloud
    • On-Premise
  • Cancer Type
    • Brain Tumor
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Skin Cancer
  • End-user
    • Cancer Centers
    • Hospitals

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the AI in Cancer Diagnostics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. AI in Cancer Diagnostics Market, by Component
  7. AI in Cancer Diagnostics Market, by Deployment
  8. AI in Cancer Diagnostics Market, by Cancer Type
  9. AI in Cancer Diagnostics Market, by End-user
  10. Americas AI in Cancer Diagnostics Market
  11. Asia-Pacific AI in Cancer Diagnostics Market
  12. Europe, Middle East & Africa AI in Cancer Diagnostics Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 378]
  17. List of Companies Mentioned [Total: 25]
How AI is Revolutionizing Cancer Diagnostics
January 8, 2024
BLOG
How AI is Revolutionizing Cancer Diagnostics
Cancer is one of the most feared diseases that has claimed millions of lives globally. Its timely and accurate diagnosis is critical for effective treatment. Traditionally, cancer diagnosis has been a tedious and time-consuming process that is often prone to inaccuracies. However, with the advent of Artificial Intelligence (AI) and Machine Learning (ML), cancer diagnostics has undergone a significant transformation.

AI-Enabled Imaging Diagnostics:

AI has significantly transformed medical imaging diagnostics by improving the accuracy of results and reducing human error. Intelligent systems can analyze large datasets to detect tiny tumor changes that human radiologists often miss. AI systems can also assess the growth and spread of tumors, providing physicians with valuable insights into the cancer's progression and informing treatment decisions.

AI-Powered Screening Programs:

AI has played a crucial role in developing several cancer screening programs worldwide. These programs leverage AI-enabled tools to screen large populations and detect early signs of cancer. By identifying cancer early on, AI has played a pivotal role in preventing cancer-related deaths.

Personalized Treatment:

AI is transforming cancer treatment by providing personalized treatment options based on patient data. AI algorithms analyze vast amounts of data to identify patterns and provide tailored treatment regimens specific to a patient's unique genetic profile. By providing personalized treatment options, AI improves patient outcomes and reduces the burden of severe side effects from traditional chemotherapy and radiation therapy.

Predictive Analytics:

AI can use machine learning algorithms to analyze large amounts of patient data, including medical records and genetic information, to predict an individual's likelihood of developing specific types of cancer. AI can identify high-risk patients early by analyzing patient data, allowing healthcare providers to take preventive measures before the cancer develops.

AI-Powered Virtual Assistants:

AI-powered virtual assistants are becoming popular tools for cancer patients and their caregivers. These assistants can help patients manage symptoms, offer medication reminders, and provide valuable information about cancer care. By providing assistance and support, these virtual assistants are enhancing the quality of life for cancer patients, enhancing treatment adherence, and reducing treatment-related stress.

AI is transforming the way cancer is diagnosed, treated, and managed. AI enhances patient outcomes while reducing healthcare costs by providing doctors with valuable insights and personalized treatment options. Integrating AI and ML into cancer diagnostics marks a significant breakthrough in the fight against cancer.

Frequently Asked Questions
  1. How big is the AI in Cancer Diagnostics Market?
    Ans. The Global AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024.
  2. What is the AI in Cancer Diagnostics Market growth?
    Ans. The Global AI in Cancer Diagnostics Market to grow USD 862.50 million by 2030, at a CAGR of 21.52%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.